ADENO-ASSOCIATED VIRUS "X" ONCOGENE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 22, 2016
app pub date -
Nov 8, 2014
filing date -
Nov 8, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A novel gene “X” of adeno-associated virus is presented, which is found to be an oncogene and to promote efficient production of recombinant AAV virus particles that may be used for human gene therapy. Since the AAV X gene appears to be an oncogene, it is desirable that it not be included in active form in recombinant AAV virus particles. Therefore A therapeutic composition comprising: a plurality of recombinant adeno-associated virus (AAV) virus particles comprising native AAV DNA and recombinant therapeutic DNA, wherein none of the AAV virus particles has an active AAV X gene is presented. Also provided are methods of expressing the X gene to improve production of recombinant AAV virus particles.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully